Latest Financial Stability News

Worley Limited has announced an ordinary unfranked dividend of AUD 0.25 per share for the six months ending June 2025, signaling steady shareholder returns amid a complex energy sector landscape.

Worley Limited reported a mixed FY2025 with a slight revenue decline but strong profitability gains and a stable dividend, signaling resilience in engineering services.

Mach7 Technologies Limited reported a 16% revenue increase to AUD 33.8 million for FY25, alongside a 22% reduction in net loss, driven by a strategic shift to subscription-based sales and disciplined cost management.

Vonex Limited reported a significantly reduced net loss for FY25 alongside a strengthened balance sheet, operational upgrades, and a pending acquisition by Maxo Telecommunications. The company is navigating going concern uncertainties while advancing network expansion and governance reforms.

EBOS Group Limited reported solid FY25 results with 12% revenue growth and strategic acquisitions, setting sights on continued expansion and operational efficiency in FY26.

DataDot Technology Limited reported a 13% revenue increase and a 56% rise in net profit after tax for FY25, driven by growth in its PropertyVAULT insurance services and new distributor partnerships.

Earlypay Ltd reported a 31% rise in statutory net profit after tax for FY25, driven by growth in equipment finance despite declines in invoice and trade finance. The company declared a fully franked final dividend of 0.65 cents per share and outlined plans to expand its lending portfolios and streamline technology.

SKS Technologies Group Limited has reported a remarkable 112% increase in net profit for the financial year ended June 2025, alongside a near doubling of revenue. The company also declared fully franked dividends, signaling confidence in its financial health.

Prime Financial Group delivered a robust FY25 performance, with revenue climbing 21% and Funds Under Management soaring 58% following a key acquisition. The company sets sights on doubling revenue within five years.

Noumi Limited has posted a significant $150 million loss for the year ending June 2025, driven by non-cash charges and raising questions about its financial stability.

Neuren Pharmaceuticals has initiated the first US investigational site for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, marking a significant milestone in addressing this rare neurodevelopmental disorder.

Vitura Health Limited has announced its third fully franked dividend of 0.2 cents per share following a profitable FY2025, reinforcing its unique position in the medicinal cannabis sector. Shareholders are invited to participate in a discounted Dividend Reinvestment Plan.